Last reviewed · How we verify
NCT07018349
Low Dose Oral Minoxdil in Androgenic Alopecia
NA trial testing 2.5% Oral minoxidil in Androgenetic Alopecia (AGA) in 76 participants. Not yet recruiting.
30 September 2025
Quick facts
| Lead sponsor | Jinnah Postgraduate Medical Centre |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 76 |
| Start date | 15 June 2025 |
| Primary completion | 30 September 2025 |
| Estimated completion | 20 October 2025 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- 2.5% Oral minoxidil — full drug profile →
- 1% Oral Minoxidil — full drug profile →
Conditions studied
- Androgenetic Alopecia (AGA) — all drugs for Androgenetic Alopecia (AGA) →
Sponsor
Jinnah Postgraduate Medical Centre — full company profile →
Who can join
Adults 18 to 65, any sex, with Androgenetic Alopecia (AGA). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In order to successfully treat androgenetic alopecia (AGA), this study compares the efficacy of low-dose oral minoxidil dosages of 0.25 mg and 1 mg. It addresses a critical gap in current research, as few studies have examined the relationship between low dosage and outcomes like hair diameter, density, patient satisfaction, and adverse effects, including hypertrichosis. Previous research suggests that low dose of oral minoxidil is a safe and well-tolerated option for hair loss, but the optimal dose for maximizing benefits while minimizing side effects remains unclear. This study aims to determine which dose offers the best balance of efficacy and safety for AGA patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07018349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Androgenetic Alopecia (AGA)
Currently open trials in the same condition.
- NCT07335367 — PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study · Phase 2 · recruiting
- NCT07011485 — A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia. · Phase 2 · active not recruiting
- NCT07079657 — Thulium Laser and Growth Factors for Androgenetic Alopecia · NA · recruiting
Other Jinnah Postgraduate Medical Centre trials
Trials by the same sponsor.
- NCT07459933 — Topical Methotrexate vs Minoxidil for Localized Alopecia Areata · Phase 4 · not yet recruiting
- NCT07438509 — Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema · Phase 4 · not yet recruiting
- NCT07256834 — Comparison of Efficacy of Betamethasone Gel With Lidocaine Gel in Prevention of Post Endotracheal Intubation Sore Throat · Phase 1, PHASE2 · not yet recruiting
- NCT07261189 — Comparing Staples Versus Polypropylene Sutures for Mesh Fixation in Inguinal Hernia Repair in Terms of Postoperative Pai · NA · completed
- NCT06821594 — Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts at Tertiary Care Hospital in Karac · EARLY_PHASE1 · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07018349 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jinnah Postgraduate Medical Centre
- Last refreshed: 12 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07018349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing